Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
Belite Bio has submitted a New Drug Application to Japan's Ministry of Health, Labour, and Welfare for tinlarebant in Stargardt disease type 1, with the application reviewed under Japan's expedited Sakigake Designation System. The Japanese filing was made side-by-side with the U.S. NDA, which the FDA has accepted with Priority Review and a PDUFA target action date of February 12, 2027. If approved, tinlarebant would be the first-ever approved treatment for STGD1 — a rare inherited retinal disease affecting an estimated 9,500 people in Japan with no current treatment options — and could become the first Sakigake-designated ophthalmology product in Japan.
Key figures
- Drug Name
- tinlarebant (LBS-008)
- Phase Of Trial
- Phase 3
- Us pathway
- FDA Priority Review with Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations
- Regulatory pathway
- Sakigake Designation System (Japan)
- Stgd1 patients japan
- 9500
- Pdufa target action date
- February 12, 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.